ARCUTIS BIOTHERAPEUTICS INC (ARQT)
US03969K1088 - Common Stock
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Arcutis today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024....
Arcutis Appoints David Topper as Chief Financial Officer
Industry veteran with over 40 years of experience in finance, investment management, and investment banking
Arcutis Appoints David Topper as Chief Financial Officer
Arcutis today announced that David Topper has been appointed Chief Financial Officer effective April 10, 2024....
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Investors Snag ARQT Even Cheaper Than Its Secondary Stock Offering
Notable Monday Option Activity: CVRX, PSA, ARQT
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement ...
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
These findings are the first to characterize the unique molecular profile of seborrheic dermatitis...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Arcutis today announced the closing of its previously announced underwritten public offering....
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Arcutis announces pricing of $150 million public offering (NASDAQ:ARQT)
Arcutis Biotherapeutics (ARQT) prices underwritten public offering of common stock, expected to raise $150 million in gross proceeds.
Arcutis Announces Pricing of $150 Million Public Offering
Arcutis Announces Pricing of $150 Million Public Offering
Arcutis today announced the pricing of its underwritten public offering of common stock....
Arcutis licenses Japanese rights for Zoryve to Sato Pharmaceutical (NASDAQ:ARQT)
Arcutis Biotherapeutics (ARQT) and Sato Pharmaceutical have entered into a licensing agreement for the commercialization of Arcutis's dermatology drug roflumilast in Japan.
Arcutis Biotherapeutics commences $150M equity raise, shares fall 6.8% (NASDAQ:ARQT)
Arcutis Biotherapeutics announces a $150M public offering of common stock and grants underwriters an option to purchase additional shares.
Arcutis Announces Proposed Public Offering
Arcutis Announces Proposed Public Offering
Arcutis today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock...
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27,...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Arcutis Biotherapeutics files for a $300M mixed securities shelf (NASDAQ:ARQT)
Arcutis Biotherapeutics files a prospectus for a $300M mixed shelf offering, but it is not an offer to sell securities.
Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference
Arcutis today announced that Arcutis management will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference....